US equities
|
SPCX
$166.85
▲+4.96%
NVDA
$236.81
▲+1.22%
MU
$1,064.20
▼-0.99%
TSLA
$377.41
▲+1.84%
MSFT
$526.59
▲+1.75%
SNDK
$1,713.46
▼-0.38%
INTC
$117.20
▼-1.78%
META
$744.95
▲+2.32%
SPCX
$166.85
▲+4.96%
NVDA
$236.81
▲+1.22%
MU
$1,064.20
▼-0.99%
TSLA
$377.41
▲+1.84%
MSFT
$526.59
▲+1.75%
SNDK
$1,713.46
▼-0.38%
INTC
$117.20
▼-1.78%
META
$744.95
▲+2.32%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Atara Biotherapeutics, Inc. - Common Stock
(NQ:
ATRA
)
9.110
-0.370 (-3.90%)
Delayed Quote
Updated: 11:51 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atara Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
April 28, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 28, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
April 25, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 24, 2026
From
Schall Law
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
April 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 21, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
April 18, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
REMINDER: Atara Biotherapeutics, Inc. Investors With Significant Losses Must Act By May 22, 2026 – Contact Kirby McInerney LLP
April 17, 2026
From
Kirby McInerney LLP
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
April 17, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 17, 2026
From
Schall Law
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
April 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 14, 2026
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
April 10, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 10, 2026
From
Schall Law
Via
GlobeNewswire
ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role
April 07, 2026
From
Kirby McInerney LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
April 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 07, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
April 06, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ATRA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Atara Biotherapeutics, Inc. Investors - Contact Kirby McInerney LLP by May 22, 2026
April 03, 2026
From
Kirby McInerney LLP
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 03, 2026
From
Schall Law
Via
GlobeNewswire
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
April 02, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Deadline Approaching: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
April 01, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
April 01, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
March 31, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 31, 2026
From
Schall Law
Via
GlobeNewswire
Law Offices of Frank R. Cruz Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
March 31, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
March 30, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
March 28, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
March 27, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
